Investment
Features
FeesSafety
Academy
More
Pluang+

Franco-Nevada CEO Paul Brink named Chair of the World Gold Council, advancing gold industry standards.

Market News
28 Sep 2026
PRNewsWire
View Source
Bullish
Franco-Nevada CEO Paul Brink named Chair of the World Gold Council, advancing gold industry standards.

Paul Brink, President & CEO of Franco-Nevada, has been appointed Chair of the World Gold Council, the leading global gold mining industry association. This role positions Brink to influence the gold sector's strategic direction, including promoting gold's role as a strategic reserve and advancing industry transparency and accountability through initiatives like the Consolidated Mining Standard. The appointment highlights Franco-Nevada's leadership in the gold market and its commitment to responsible mining practices. The World Gold Council continues to support gold's importance in the financial system and sustainable industry standards.

The appointment of Paul Brink as Chair of the World Gold Council is notable news. For readers following the broader market, here is Pluang's snapshot as of Sep 29, 2026 02:21 WIB: out of 150 priced US stocks tradable on Pluang, 38 rose and 110 fell. Notable movers include AFRM at USD 68.15 with a -4.71% change, META at USD 718.86 with a -4.36% change, and RIVN at USD 14.84 with a -4.10% change.

More News

RGA stock set for 16.7% rise on strong earnings and favorable market conditions

RGA stock set for 16.7% rise on strong earnings and favorable market conditions

Morgan Stanley raised the price target for Reinsurance Group of America (RGA) to $295, implying a 16.7% upside from its current price of $252.85. The company reported a 42% increase in adjusted operating income to $746 million in H1, driven by its lo...

Analyst Insights
Bullish
1 hour ago
Mirum Pharmaceuticals' price target raised to $195 after key drug approvals and trial success

Mirum Pharmaceuticals' price target raised to $195 after key drug approvals and trial success

H.C. Wainwright raised Mirum Pharmaceuticals' price target from $140 to $195 following positive developments: the Phase 3 AZURE-1 trial for Brelovitug met its main goal for treating Chronic Hepatitis Delta Virus, and the FDA approved Atebrioz™ for Fi...

Analyst Insights
Bullish
2 hours ago
Kodiak Sciences stock jumps 176% after positive Phase 3 trial for retinal disease drug

Kodiak Sciences stock jumps 176% after positive Phase 3 trial for retinal disease drug

Kodiak Sciences reported successful Phase 3 trial results for its retinal disease treatments Zenkuda and tabirafusp-ted, showing vision improvements comparable to Regeneron's Eylea. Zenkuda allowed 54% of patients to maintain a six-month dosing inter...

Market News
Bullish
3 hours ago
Citigroup keeps Neutral on Regeneron amid rising competition from Kodiak Sciences' eye drug success

Citigroup keeps Neutral on Regeneron amid rising competition from Kodiak Sciences' eye drug success

Citigroup has maintained a Neutral rating on Regeneron Pharmaceuticals due to increasing competition in the ophthalmology sector. Kodiak Sciences reported positive Phase 3 trial results for its eye drugs, challenging Regeneron's key product, Eylea, e...

Analyst Insights
Neutral
3 hours ago
ICF awarded $70M to support SoCalREN's energy efficiency programs in Southern California.

ICF awarded $70M to support SoCalREN's energy efficiency programs in Southern California.

ICF has secured two new multiyear contracts worth about $70 million to implement energy efficiency programs for the Southern California Regional Energy Network (SoCalREN). These programs aim to reduce energy costs, enhance grid reliability, and suppo...

Market News
Bullish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App